key: cord-1034445-ijfvjfth
authors: Monzani, Alice; Lionetti, Paolo; Rabbone, Ivana; Lionetti, Elena
title: The best is the enemy of the good: Time for a biopsy‐sparing approach for Helicobacter pylori diagnosis and treatment in children in the COVID‐19 era?
date: 2021-05-28
journal: Helicobacter
DOI: 10.1111/hel.12826
sha: a179dfd755cb301c09fc9aad52eddaf6b0958414
doc_id: 1034445
cord_uid: ijfvjfth

nan

The best is the enemy of the good: Time for a biopsy-sparing approach for Helicobacter pylori diagnosis and treatment in children in the COVID-19 era?

To the Editor,

The Joint ESPGHAN/NASPGHAN Guidelines for the

Adolescents recommend against a "test and treat" strategy for H. pylori infection, while recommending antimicrobial sensitivity testing and tailoring eradication therapy accordingly. 1 It is strongly recommended (with a high quality of evidence and 100% agreement) that We suggest that, in children likely having H. pylori-associated gastritis or peptic ulcer disease on the basis of the presenting symptoms, the diagnosis of H. pylori infection might be made by non-invasive tests, either a 13 C-urea breath test (UBT) or a stool 2step monoclonal H. pylori antigen test, and an empiric eradication strategy could be adopted. In line with the treatment suggested by the Joint ESPGHAN/NASPGHAN Guidelines in the case of unknown clarithromycin resistance status, a therapeutic approach with high-dose proton-pump inhibitor, amoxicillin, and metronidazole or bismuth-based therapy can be attempted. In addition to the known high rate of clarithromycin resistance in Europe (25% in the pediatric population), 5 it is possible that primary resistance to clarithromycin could become even higher due to the widespread use of another macrolide antibiotic, azithromycin, in some therapeutic lines for COVID-19. 6 Undoubtedly, eradication should be assessed at least 4 weeks after completion of therapy by either a 13 C-UBT or a stool 2-step monoclonal H. pylori antigen test, as suggested by the Joint ESPGHAN/NASPGHAN guidelines, 1 and upper gastrointestinal endoscopy should be considered in case of eradication failure or persisting symptoms. We understand that this approach is far from the gold standard management recommended by the existing guidelines, but in this critical period in which the priorities have been necessarily revised, a temporary exception might be considered, only in the areas where strict adherence to the guidelines would be more harmful than beneficial, leaving symptomatic children untreated for a long time. This exception to the current guidelines may also be considered for high risk, low-income populations, for whom the pretest probability is higher and the upper endoscopy with anesthesia is an obstacle.

The authors are grateful to Professor Giuseppina Oderda, a constant source of help and guidance.

The authors have no competing interests to disclose related to this article. 

Joint ESPGHAN/ NASPGHAN guidelines for the management of helicobacter pylori in children and adolescents (Update

ESGE and ESGENA position statement on gastrointestinal endoscopy and the COVID-19 pandemic

Changes in pediatric endoscopic practice during the coronavirus disease 2019 pandemic: results from an international survey

ESPGHAN 'biopsysparing' guidelines for celiac disease in children with low antitransglutaminase during COVID-19

Helicobacter pylori infection in pediatric patients living in Europe: results of the EuroPedHP registry 2013 to 2016

Novel coronavirus disease (COVID-19) update on epidemiology, pathogenicity, clinical course and treatments

The best is the enemy of the good: Time for a biopsy-sparing approach for Helicobacter pylori diagnosis and treatment in children in the COVID-19 era?